- •Metastatic gastric and oesophageal cancers are associated with a poor prognosis.
- •Chemotherapy and artificial nutrition at the end of life are of questionable benefit.
- •Use of chemotherapy nutrition decreased as death approaches.
- •Use of artificial nutrition increases steadily in the final weeks of life.
To evaluate the frequency and the factors associated with the use of chemotherapy and artificial nutrition near the end of life in hospitalised patients with metastatic oesophageal or gastric cancer.
Nationwide, register-based study, including all hospitalised adults (≥20 years) who died with metastatic oesophageal or gastric cancer between 2010 and 2013, in France. Chemotherapy and artificial nutrition during the final weeks of life were considered as primary outcomes.
A total of 4031 patients with oesophageal cancer and 10,423 patients with gastric cancer were included. While the proportion of patients receiving chemotherapy decreased from 35.9% during the 3rd month before death to 7.9% in the final week (p < 0.001 for trend), the use of artificial nutrition rose from 9.6% to 16.0% of patients. During the last week before death, patients with stomach cancer were more likely to receive chemotherapy (adjusted odds ratio (aOR) = 1.35, 95% CI = 1.17–1.56) but less likely to receive artificial nutrition (aOR = 0.80, 95%CI = 0.73–0.88) than patients with cancer of the oesophagus. The adjusted rates of chemotherapy use during the last week of life varied from 1.6% in rural hospitals to 11.2% in comprehensive cancer centres, while the adjusted probability to receive artificial nutrition varied from 12.1% in private for-profit clinics up to 19.9% in rehabilitation care facilities (p < 0.001).
Our study shows that in hospitalised patients with metastatic oesophageal or gastric cancer, the use of chemotherapy decreases while the use of artificial nutrition increases as death approaches. This raises important questions, as clinical guidelines clearly recommend to limit the use of artificial nutrition in contexts of limited life expectancy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer. 2015; 136: E359-E386https://doi.org/10.1002/ijc.29210
- Update on metastatic gastric and oesophageal cancers.J Clin Oncol. 2015; 33: 1760-1769https://doi.org/10.1200/JCO.2014.60.1799
- Survival for esophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5.Eur J Cancer. 2015; 51: 2144-2157https://doi.org/10.1016/j.ejca.2015.07.026
- Early palliative care for patients with metastatic non-small-cell lung cancer.N Engl J Med. 2010; 363: 733-742https://doi.org/10.1056/NEJMoa1000678
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.Lancet. 2014; 383: 1721-1730https://doi.org/10.1016/S0140-6736(13)62416-2
- Impact of aggressive management and palliative care on cancer costs in the final month of life.Cancer. 2015; 121: 3307-3315https://doi.org/10.1002/cncr.29485
- The effect on survival of continuing chemotherapy to near death.BMC Palliat Care. 2011; 10: 14https://doi.org/10.1186/1472-684X-10-14
- Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study.BMJ. 2014; 348: g1219https://doi.org/10.1136/bmj.g1219
- Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?.J Clin Oncol. 2008; 26: 3860-3866https://doi.org/10.1200/JCO.2007.15.8253
- American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.J Clin Oncol. 2012; 30: 1715-1724https://doi.org/10.1200/JCO.2012.42.8375
- The role of chemotherapy at the end of life: “when is enough, enough?”.JAMA. 2008; 299: 2667-2678https://doi.org/10.1001/jama.299.22.2667
- Importance of early nutritional screening in patients with gastric cancer.Br J Nutr. 2011; 106: 1773-1778https://doi.org/10.1017/S0007114511002509
- Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres.Br J Cancer. 2010; 102: 966-971https://doi.org/10.1038/sj.bjc.6605578
- An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer.Clin Nutr. 2005; 24: 801-814https://doi.org/10.1016/j.clnu.2005.05.001
- Parenteral nutrition support for patients with pancreatic cancer–improvement of the nutritional status and the therapeutic outcome.Anticancer Res. 2012; 32: 2111-2118
- Nutritional support in patients with esophageal cancer.Support Care Cancer. 2010; 18: S41-S50https://doi.org/10.1007/s00520-009-0664-9
- Enteral and parenteral nutrition in cancer patients: a systematic review and meta-analysis.Ann Palliat Med. 2016; 5: 30-41https://doi.org/10.3978/j.issn.2224-5820.2016.01.01
- Nutritional support at the end of life.Nutrition. 2015; 31: 615-616https://doi.org/10.1016/j.nut.2014.12.004
- ESPEN guidelines on parenteral nutrition: non-surgical oncology.Clin Nutr. 2009; 28: 445-454https://doi.org/10.1016/j.clnu.2009.04.011
- The role of overdiagnosis and reclassification in the marked increase of oesophageal adenocarcinoma incidence.J Natl Cancer Inst. 2005; 97: 142-146https://doi.org/10.1093/jnci/dji024
- Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries.JAMA. 2016; 315: 272-283https://doi.org/10.1001/jama.2015.18603
- Trends in the aggressiveness of cancer care near the end of life.J Clin Oncol. 2004; 22: 315-321https://doi.org/10.1200/JCO.2004.08.136
- Quality of end-of-life cancer care for medicare beneficiaries; regional and hospital-specific analyses. A report of the Dartmouth Atlas Project.The Dartmouth Institute for Health Policy & Clinical Practice, 2010 (Available at:)
- Chemotherapy use in the months before death and estimated costs of care in the last week of life.J Pain Symptom Manage. 2016; 51 (875–881.e2)https://doi.org/10.1016/j.jpainsymman.2015.12.323
- A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer.BMJ Open. 2015; 5: e006724https://doi.org/10.1136/bmjopen-2014-006724
- Chemotherapy use, performance status, and quality of life at the end of life.JAMA Oncol. 2015; 1: 778-784https://doi.org/10.1001/jamaoncol.2015.2378
- End-of-life care for medicare beneficiaries with cancer is highly intensive overall and varies widely.Health Aff. 2012; 31: 786-796https://doi.org/10.1377/hlthaff.2011.0650
- Definition and classification of cancer cachexia: an international consensus.Lancet Oncol. 2011; 12: 489-495https://doi.org/10.1016/S1470-2045(10)70218-7
- Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition.Ann Oncol. 2015; 26: 2335-2340https://doi.org/10.1093/annonc/mdv365
- The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.Gynecol Oncol. 2006; 103: 176-180https://doi.org/10.1016/j.ygyno.2006.02.013
- Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects.Ann Oncol. 2011; 22: 1478-1486https://doi.org/10.1093/annonc/mdq620
- Patient-reported outcomes as end points and outcome indicators in solid tumours.Nat Rev Clin Oncol. 2015; 12: 358-370https://doi.org/10.1038/nrclinonc.2015.29
- A systematic review of physicians' survival predictions in terminally ill cancer patients.BMJ. 2003; 327: 195-198https://doi.org/10.1136/bmj.327.7408.195
- ESPEN guideline on ethical aspects of artificial nutrition and hydration.Clin Nutr. 2016; 35: 545-556https://doi.org/10.1016/j.clnu.2016.02.006
- Patients' expectations about effects of chemotherapy for advanced cancer.N Engl J Med. 2012; 367: 1616-1625https://doi.org/10.1056/NEJMoa1204410
- Discussions of life expectancy and changes in illness understanding in patients with advanced cancer.J Clin Oncol. 2016; 34: 2398-2403https://doi.org/10.1200/JCO.2015.63.6696
- Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient.J Clin Oncol. 2009; 27: 2225-2230https://doi.org/10.1200/JCO.2008.17.9515
- Integrating palliative care into the trajectory of cancer care.Nat Rev Clin Oncol. 2015; 13: 159-171https://doi.org/10.1038/nrclinonc.2015.201
- Decision making at the end of life–cancer patients' and their caregivers' views on artificial nutrition and hydration.Support Care Cancer. 2014; 22: 3287-3299https://doi.org/10.1007/s00520-014-2337-6
- Resurrecting treatment histories of dead patients: a study design that should be laid to rest.JAMA. 2004; 292: 2765-2770https://doi.org/10.1001/jama.292.22.2765
- End-of-life medical decisions in France: a death certificate follow-up survey 5 years after the 2005 act of parliament on patients' rights and end of life.BMC Palliat Care. 2012; 11: 25https://doi.org/10.1186/1472-684X-11-25
Published online: April 27, 2017
Accepted: March 26, 2017
Received in revised form: March 16, 2017
Received: November 15, 2016
© 2017 Elsevier Ltd. All rights reserved.